Tesla makes a rare U-turn after it reveals that some of its cars scheduled for February delivery in China will be delayed due to the coronavirus outbreak.
Shares of Tesla TSLA made a rare U-turn on Wednesday after the electric automaker said that some of its cars scheduled for February delivery in China will be delayed due to the coronavirus outbreak, which has kept its Shanghai plant shuttered for nearly two weeks.
Tesla shares fell 18.84% to $719.95 on Wednesday after a company executive confirmed that expected deliveries of the electric vehicle company's Model 3 sedans will be delayed as Tesla’s Shanghai factory remains closed following the Chinese Lunar New Year.
“The proposed delivery (of cars) in early February will be delayed,” Tao Lin, vice president at Tesla, said on the Chinese microblogging service Weibo. “We will catch up the production line once the outbreak situation gets better.”
The electric carmaker began rolling out Model 3 vehicles from its Shanghai Gigafactory to Chinese customers in January.
Shares of Tesla soared more than 36% over the past two sessions, and had rocketed nearly 60% through Tuesday on the back of strong earnings and expectations of more to come.
- Tesla's Impressive Quarter: What Analysts Are Saying
- Tesla Shares Zoom Past $700 on Analyst Upgrades
- Jim Cramer on Whether or Not Tesla's Stock Has a Mind of Its Own
Tesla surged almost 20% on Monday alone, pushing its market value close to $141 billion, after Panasonic said it turned profitable in the final quarter of 2019, a full quarter ahead of expectations, thanks to battery sales to Tesla.
Tesla is now well ahead of fellow domestic carmakers Ford F and General Motors GM in terms of market cap, with Toyota TM well within its sights. Yet Toyota sold 10.74 million cars in 2019 compared to 367,500 for Tesla.
Analysts recently have been raising price targets to catch up to the stock and short-covering by investors betting against the shares. The average 12-month price target of analysts is now $493, up from $334 in December, according to FactSet.
However, Jed Dorsheimer with Canaccord Genuity took a different road on Wednesday, telling clients in a research note that his team is “taking our foot off the accelerator” and downgrading the stock to hold from buy in part because of the stock's run-up but also because of concerns about the impact of the coronavirus.
“Just as we observed a clear buy signal coming into 2020, we see the risk of China's
coronavirus as a clear headwind to the Shanghai facility, suggesting a more pragmatic position,” said Dorsheimer.
He reiterated his $750 stock price target, however.
This news is provided by The Street RSS Feed, All credits go to The Street.
Disclaimer: All posts made on this website are provided for information purposes only. None of the information here is intended as investment advice, as an offer or solicitation of an offer to buy or sell, or as a recommendation, endorsement, or sponsorship of any security, Company, or fund. Before making an investment decision, you should seek the advice of a qualified and registered securities professional. The author is not paid to share this information. Cannabis Investment Group is not paid to share this information and has no business relationship other than shareholder with any company whose stock is mentioned in this article.